Transdermal Drug Delivery: More Than Skin Deep

Start-ups continue to seize opportunities for delivering new and existing drugs transdermally. They are also poised to capitalize on next-generation technologies for delivering macromolecules through the skin. In this issue, we profile AllTranz, Ocelus, Quinnova Pharmaceuticals and Syntropharma.

The idea of taping an adhesive patch filled with a drug or rubbing a drug-laced cream into the skin makes intuitive sense. Such products are easy to use, noninvasive, nonintrusive, don't upset the stomach, and with long-release formulations one application lasts many hours or even days. The first blockbuster transdermal drug, the nicotine patch, suppresses a smoker's craving for cigarettes with a steady 16-hour trickle of nicotine; the fentanyl patch provides 72 hours of pain relief; and women who use contraceptive patches apply them just once a week. However, at present only 20 marketed drugs come in FDA-approved transdermal patches and about 100 more are absorbed through the skin in ointment or gel formulations. The limitations of present transdermal drug delivery systems – particularly the skin's imperviousness to macromolecules – hold back growth. Several recent moves by Big Pharma, though, indicate a continuing and possibly growing interest in coming up with transdermal formulations for new and existing drugs, and numerous biotechs, including the four profiled in this issue, believe they can find exciting new ways to capitalize on the transdermal opportunity, particularly as specialty pharmaceuticals have increasingly come to the fore.

Stuck to the skin, patches work passively to diffuse a drug across the stratum corneum, the lipid and remnant epidermal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.